Yen Ying Lim1, Elizabeth C Mormino2. 1. From the Florey Institute of Neuroscience and Mental Health (Y.Y.L.), The University of Melbourne, Parkville, Australia; and the Department of Neurology and Neurological Sciences (E.C.M.), Stanford University, CA. 2. From the Florey Institute of Neuroscience and Mental Health (Y.Y.L.), The University of Melbourne, Parkville, Australia; and the Department of Neurology and Neurological Sciences (E.C.M.), Stanford University, CA. bmormino@stanford.edu.
Abstract
OBJECTIVE: To clarify associations between APOE ε4 allele and age on longitudinal rates of β-amyloid (Aβ) accumulation within Aβ+ and Aβ- older individuals without dementia. METHODS: We analyzed 595 older adults without dementia classified cross-sectionally as Aβ- (n = 325) and Aβ+ (n = 270) using longitudinal florbetapir PET. The influence of age and APOE genotype on longitudinal accumulation of Aβ was examined with linear mixed models. RESULTS: APOE ε4 and older age were associated with higher risk of being classified as Aβ+ at baseline. The annual rate of Aβ accumulation was significantly greater than zero for Aβ- ε3 (0.0021 ± 0.0007 standardized uptake value ratio [SUVR] units) and Aβ- ε4 (0.0044 ± 0.0010 SUVR units), as well as Aβ+ ε3 (0.0141 ± 0.0019 SUVR units) and Aβ+ ε4 (0.0126 ± 0.0018 SUVR units). Aβ accumulation was significantly faster in Aβ- ε4 compared to Aβ- ε3 and Aβ- ε2. Rates of Aβ accumulation did not differ significantly between Aβ+ APOE groups. Older age was associated with higher rates of Aβ accumulation in the Aβ- group. CONCLUSIONS: APOE ε4 carriage and older age were predictors of longitudinal Aβ accumulation within the Aβ- group but not the Aβ+ group. APOE ε2 carriage was protective against longitudinal Aβ accumulation within the Aβ- group. APOE genotype in conjunction with chronologic age may aid in participant selection for primary prevention trials aimed at halting Aβ accumulation before abnormal levels are reached.
OBJECTIVE: To clarify associations between APOE ε4 allele and age on longitudinal rates of β-amyloid (Aβ) accumulation within Aβ+ and Aβ- older individuals without dementia. METHODS: We analyzed 595 older adults without dementia classified cross-sectionally as Aβ- (n = 325) and Aβ+ (n = 270) using longitudinal florbetapir PET. The influence of age and APOE genotype on longitudinal accumulation of Aβ was examined with linear mixed models. RESULTS: APOE ε4 and older age were associated with higher risk of being classified as Aβ+ at baseline. The annual rate of Aβ accumulation was significantly greater than zero for Aβ- ε3 (0.0021 ± 0.0007 standardized uptake value ratio [SUVR] units) and Aβ- ε4 (0.0044 ± 0.0010 SUVR units), as well as Aβ+ ε3 (0.0141 ± 0.0019 SUVR units) and Aβ+ ε4 (0.0126 ± 0.0018 SUVR units). Aβ accumulation was significantly faster in Aβ- ε4 compared to Aβ- ε3 and Aβ- ε2. Rates of Aβ accumulation did not differ significantly between Aβ+ APOE groups. Older age was associated with higher rates of Aβ accumulation in the Aβ- group. CONCLUSIONS: APOE ε4 carriage and older age were predictors of longitudinal Aβ accumulation within the Aβ- group but not the Aβ+ group. APOE ε2 carriage was protective against longitudinal Aβ accumulation within the Aβ- group. APOE genotype in conjunction with chronologic age may aid in participant selection for primary prevention trials aimed at halting Aβ accumulation before abnormal levels are reached.
Authors: Andrei G Vlassenko; Mark A Mintun; Chengjie Xiong; Yvette I Sheline; Alison M Goate; Tammie L S Benzinger; John C Morris Journal: Ann Neurol Date: 2011-11 Impact factor: 10.422
Authors: Jon B Toledo; Henrik Zetterberg; Argonde C van Harten; Lidia Glodzik; Pablo Martinez-Lage; Luisella Bocchio-Chiavetto; Lorena Rami; Oskar Hansson; Reisa Sperling; Sebastiaan Engelborghs; Ricardo S Osorio; Hugo Vanderstichele; Manu Vandijck; Harald Hampel; Stefan Teipl; Abhay Moghekar; Marilyn Albert; William T Hu; Jose A Monge Argilés; Ana Gorostidi; Charlotte E Teunissen; Peter P De Deyn; Bradley T Hyman; Jose L Molinuevo; Giovanni B Frisoni; Gurutz Linazasoro; Mony J de Leon; Wiesje M van der Flier; Philip Scheltens; Kaj Blennow; Leslie M Shaw; John Q Trojanowski Journal: Brain Date: 2015-07-27 Impact factor: 13.501
Authors: Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun Journal: J Nucl Med Date: 2012-11-19 Impact factor: 10.057
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: B T Hyman; T Gomez-Isla; G W Rebeck; M Briggs; H Chung; H L West; S Greenberg; S Mui; S Nichols; R Wallace; J H Growdon Journal: Ann N Y Acad Sci Date: 1996-12-16 Impact factor: 5.691
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Katherine J Bangen; Alexandra L Clark; Madeline Werhane; Emily C Edmonds; Daniel A Nation; Nicole Evangelista; David J Libon; Mark W Bondi; Lisa Delano-Wood Journal: J Alzheimers Dis Date: 2016-03-29 Impact factor: 4.472
Authors: Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli Journal: Alzheimers Res Ther Date: 2013-09-03 Impact factor: 6.982
Authors: Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu Journal: Neurobiol Aging Date: 2020-05-31 Impact factor: 4.673
Authors: Rachel F Buckley; Elizabeth C Mormino; Rebecca E Amariglio; Michael J Properzi; Jennifer S Rabin; Yen Ying Lim; Kathryn V Papp; Heidi I L Jacobs; Samantha Burnham; Bernard J Hanseeuw; Vincent Doré; Annette Dobson; Colin L Masters; Michael Waller; Christopher C Rowe; Paul Maruff; Michael C Donohue; Dorene M Rentz; Dylan Kirn; Trey Hedden; Jasmeer Chhatwal; Aaron P Schultz; Keith A Johnson; Victor L Villemagne; Reisa A Sperling Journal: Alzheimers Dement Date: 2018-05-24 Impact factor: 21.566
Authors: Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Jennifer L Dearborn; Anna M Kucharska-Newton; Juebin Huang; Alvaro Alonso; Rebecca F Gottesman Journal: JAMA Neurol Date: 2018-11-01 Impact factor: 18.302
Authors: Samantha C Burnham; Simon M Laws; Charley A Budgeon; Vincent Doré; Tenielle Porter; Pierrick Bourgeat; Rachel F Buckley; Kevin Murray; Kathryn A Ellis; Berwin A Turlach; Olivier Salvado; David Ames; Ralph N Martins; Dorene Rentz; Colin L Masters; Christopher C Rowe; Victor L Villemagne Journal: Neurobiol Aging Date: 2020-06-10 Impact factor: 4.673
Authors: Annah M Moore; Emily Mahoney; Logan Dumitrescu; Philip L De Jager; Mary Ellen I Koran; Vladislav A Petyuk; Renã As Robinson; Douglas M Ruderfer; Nancy J Cox; Julie A Schneider; David A Bennett; Angela L Jefferson; Timothy J Hohman Journal: Neurobiol Aging Date: 2019-11-05 Impact factor: 4.673
Authors: Rachel F Buckley; Elizabeth C Mormino; Jasmeer Chhatwal; Aaron P Schultz; Jennifer S Rabin; Dorene M Rentz; Diler Acar; Michael J Properzi; Julien Dumurgier; Heidi Jacobs; Teresa Gomez-Isla; Keith A Johnson; Reisa A Sperling; Bernard J Hanseeuw Journal: Neurobiol Aging Date: 2019-03-07 Impact factor: 4.673
Authors: Rachel F Buckley; Elizabeth C Mormino; Jennifer S Rabin; Timothy J Hohman; Susan Landau; Bernard J Hanseeuw; Heidi I L Jacobs; Kathryn V Papp; Rebecca E Amariglio; Michael J Properzi; Aaron P Schultz; Dylan Kirn; Matthew R Scott; Trey Hedden; Michelle Farrell; Julie Price; Jasmeer Chhatwal; Dorene M Rentz; Victor L Villemagne; Keith A Johnson; Reisa A Sperling Journal: JAMA Neurol Date: 2019-05-01 Impact factor: 18.302